טוען...
Current status of biosimilars in the treatment of inflammatory bowel diseases
Introduction of biological therapies have led to dramatic changes in the management of debilitating immune-mediated inflammatory bowel diseases (IBD) including ulcerative colitis and Crohn's disease. However, the long term use of these agents may be very expensive, placing a significant burden...
שמור ב:
| הוצא לאור ב: | Intest Res |
|---|---|
| מחבר ראשי: | |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Korean Association for the Study of Intestinal Diseases
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4754516/ https://ncbi.nlm.nih.gov/pubmed/26884730 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5217/ir.2016.14.1.15 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|